Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy

Autor: Graham Pawelec, Christopher Shipp, Robert M. Lafrenie, Lisa Speigl, Carly A. Buckner, Michael Conlon
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
Adult
Cancer Research
medicine.medical_specialty
Paclitaxel
T cell
medicine.medical_treatment
Breast Neoplasms
CD8-Positive T-Lymphocytes
Vinblastine
Peripheral blood mononuclear cell
Monocytes
Carboplatin
Cohort Studies
03 medical and health sciences
0302 clinical medicine
Immunophenotyping
Breast cancer
Lymphocytes
Tumor-Infiltrating
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Neoplasm Metastasis
Cyclophosphamide
Chemotherapy
business.industry
Cancer
Dendritic Cells
Middle Aged
medicine.disease
Prognosis
Metastatic breast cancer
Survival Rate
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
Leukocytes
Mononuclear
Female
Mitoxantrone
Neoplasm Recurrence
Local
business
CD8
Thiotepa
Follow-Up Studies
Zdroj: Clinical breast cancer. 19(6)
ISSN: 1938-0666
Popis: Background The frequency of circulating leukocytes has been shown to be a prognostic factor in patients being treated for different types of cancer. In breast cancer, tumor-infiltrating leukocytes may predict patient outcome, but few studies have investigated such associations for circulating leukocytes. Patients and Methods Multiparametric flow cytometry was used to examine the immunophenotypes of circulating peripheral blood mononuclear cells for 88 patients with metastatic breast cancer, which was then correlated to breast cancer–specific survival. Patients had been treated either with high-dose cyclophosphamide-containing regimens (group 1, n = 51 patients) or high-dose paclitaxel-containing regimens (group 2, n = 37 patients). Results The frequency of peripheral blood CD14+ monocytes indicated prognosis for patients in group 1 (but not group 2), while higher levels of CD11c+ dendritic cells indicated a better prognosis for patients in group 2 (but not group 1). The frequency of a number of different CD4+ or CD8+ T cell subtypes also predicted prognosis for patients in group 2. For example, patients in group 2 with a higher frequency of circulating CD4+ or CD8+ naive T cells (CD45RA+CD95−CD27+CD28+) showed a poorer prognosis. In contrast, T cells were not associated with prognosis for patients in group 1. Conclusion Circulating leukocytes can predict clinical outcome for patients with breast cancer. Prediction of clinical outcome in this cohort of metastatic breast cancer patients was specific to the type of chemotherapy, and this finding is likely to apply to other therapies.
Databáze: OpenAIRE
Externí odkaz: